DelveInsight’s, “Gastric Cancer Pipeline Insight 2023” report provides comprehensive insights about 230+ companies and 230+ pipeline drugs in the Gastric Cancer pipeline landscape. It covers the Gastric Cancer pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Gastric Cancer Pipeline Report
To explore more information on the latest breakthroughs in the Gastric Cancer Pipeline treatment landscape of the report, click here @ Gastric Cancer Pipeline Outlook
Gastric Cancer Overview
Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It’s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked to a bacteria that lives in the stomach called Helicobacter pylori. But not everyone with Helicobacter pylori will develop stomach cancer.
Recent Developments Activities in the Gastric Cancer Treatment Landscape
For further information, refer to the detailed Gastric Cancer Unmet Needs, Gastric Cancer Market Drivers, and Gastric Cancer Market Barriers, click here for Gastric Cancer Ongoing Clinical Trial Analysis
Gastric Cancer Emerging Drugs Profile
IBI308 is a fully human monoclonal antibody that blocking programmed death protein-1. Innovent holds the global intellectual property rights of IBI308. Currently IBI308 has been approved for marketing by the NMPA. Acting as an immune checkpoint inhibitor by targeting PD-1, IBI308 boosts the immune response against tumor cells and inhibits the immune escape of tumor cells. Currently, it is in Phase III stage of clinical trial evaluation to treat gastric cancer.
It is a recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection independently researched and developed by Henlius, is for the treatment of various solid tumors and can be applied in combination with other products for immuno-oncology therapy. Currently, it is in Phase III stage of clinical trial evaluation to treat gastric cancer.
It is an investigational small molecule inhibitor of the PARP1 and PARP2 enzymes that is being evaluated as a potential monotherapy and in combination with other therapies to treat various solid tumors. Pamiparib’s early compound name was BGB-290. Currently, it is in Phase II stage of clinical trial evaluation to treat gastric cancer.
Gastric Cancer Pipeline Therapeutic Assessment
There are approx. 230+ key companies which are developing the therapies for Gastric Cancer. The companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.
Request a sample and discover the recent advances in Gastric Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Gastric Cancer Treatment Landscape
Scope of the Gastric Cancer Pipeline Report
Dive deep into rich insights for drugs for Gastric Cancer Market Drivers and Gastric Cancer Market Barriers, click here @ Gastric Cancer Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Gastric Cancer Mergers and acquisitions, Gastric Cancer Licensing Activities @ Gastric Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services